Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group PLC – Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
Avacta Group PLC (AIM:AVCT) Preliminary Results for the year ended 31 December 2022
A period of continued significant progress
Avacta Group PLC (AIM:AVCT) AVA3996 data poster presented at AACR
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Avacta shares: brief update for Q2 2023
Avacta has expanded its footprint in the US. The listing could be next.
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center are now open for patient enrolment to pre|CISION™ lead programme, AVA6000
Avacta Group PLC (AIM:AVCT) First Patient Dosed in Fifth Cohort of AVA6000
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
Abingdon Health PLC (AIM:ABDX) Senzo and Abingdon Health enter into strategic partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Abingdon Health PLC (AIM:ABDX) AppDx ® lateral flow smartphone reader granted further patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Abingdon Health PLC (AIM:ABDX) Trading Update
York, U.K. 28 February 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months